OvaScience’s EggPC Technology Recognized by Science as a Top Ten Advancement in Reproductive Medicine
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 8, 2014-- OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Science magazine has named OvaScience's egg precursor cell (EggPCSM) technology, as described in the March 2012 Nature Medicine publication, one of the top ten papers in reproductive medicine. The publication challenged the existing paradigm that women are born with a set number of eggs, and demonstrated for the first time that EggPCs found on the ovaries can be matured into young, healthy eggs. The article by
"This seminal paper on EggPCs and the research that led to its publication have played a fundamental role in the development of our fertility product pipeline," said
The Science supplement, titled "Ten Critical Topics in Reproductive Medicine" provides a broad review of papers selected by an expert panel as the most impactful journal articles in the field.
This press release includes forward-looking statements about the prospects for the Company's technology in addressing female infertility and the Company's strategy, future plans and prospects, including statements regarding the planned discovery, development and commercialization of the Company's product candidates. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "aim," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates (AUGMENT and OvaTure), which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the "Risk Factors" section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.
Theresa McNeely, 617-299-7356
EVP, Strategic Corporate Communications